FDA Turns Back To CME as Opioid Control Tool
This article was originally published in RPM Report
Executive Summary
Continuing medical education has been under attack in Washington in recent years, criticized as representing a way around FDA’s control of medical promotion. Now, FDA is turning back to CME as the keystone to controlling a tough drug overuse/abuse situation.